Last updated: March 1, 2026
What is NDC 70677-1061?
NDC 70677-1061 refers to a specific pharmaceutical product registered with the National Drug Code (NDC) system. Based on publicly available information, this NDC is associated with Aflibercept (Eylea), a monoclonal anti-VEGF agent used primarily for treating retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Market Overview
Therapeutic Area
Aflibercept is a leading drug in ocular anti-VEGF therapy, competing with Ranibizumab (Lucentis) and Bevacizumab (Avastin). The global market for intravitreal anti-VEGF agents was valued at approximately $8.4 billion in 2022, with a forecast CAGR of 3.8% through 2030 (Grand View Research).
Key Market Drivers
- Aging population increasing AMD prevalence.
- Growing diabetic population and DME incidence.
- Technological improvements reducing injection frequency.
- Expanded indications, including myopic choroidal neovascularization.
Market Players
Dominate market share, notably:
| Company |
Product |
Market Share (2022) |
Pricing Basis |
| Regeneron |
Eylea |
60% |
Price per injection varies, estimated at $1,900-$2,100 |
| Roche (Genentech) |
Lucentis |
25% |
Similar pricing, roughly $1,800-$2,000 |
| Bayer |
Beovu |
2-3% |
Slightly higher due to dosing frequency |
Market Trends
- Increasing adoption of longer-lasting formulations.
- Compassionate use and biosimilars gradually entering the market.
- Price pressure from government negotiations and insurance providers.
Pricing Trends and Projections
Current Price Points (2023)
- Injection cost: $1,900-$2,100 for branded Eylea.
- Average annual treatment cost: $20,000-$30,000, assuming roughly 10 injections per year.
Factors Influencing Price Projections
- Patent expiration: Eylea's patent in the US expires in October 2024, opening market access for biosimilars.
- Regulatory approvals: Biosimilars approved in Europe and India, expected to enter the US market post-2024.
- Market penetration: Biosimilar pricing anticipated to be 20-30% lower than branded drug.
- Reimbursement policies: Negotiations expected to push prices downward, especially amid healthcare cost containment.
Price Projection (2024-2030)
| Year |
Estimated Price per Injection |
Notes |
| 2024 |
$1,200 - $1,500 |
Entry of biosimilars; initial pricing |
| 2025 |
$1,000 - $1,300 |
Increased biosimilar market share |
| 2026 |
$900 - $1,200 |
Competitive pressures intensify |
| 2028 |
$800 - $1,000 |
Biosimilar dominance established |
| 2030 |
$700 - $900 |
Further price compression |
Revenue Impact
Assuming a conservative dose reduction and increased biosimilar adoption, US market revenues could decrease from approximately $4 billion in 2023 to $2.8 billion by 2030.
Competitive Landscape
| Product |
Company |
Patent Status |
Price Range (per injection) |
Market Share (2022) |
| Eylea |
Regeneron |
Patent valid until 2024 |
$1,900-$2,100 |
60% |
| Lucentis |
Roche |
Patent expired 2018 |
$1,800-$2,000 |
25% |
| Beovu |
Bayer |
Patent pending (as of 2022) |
$1,850-$2,100 |
2-3% |
| Biosimilars |
Various |
Approved in Europe, India |
Expected 20-30% discount |
Emerging competition |
Regulatory Environment Impact
- Biosimilar approvals in the US are scheduled for the post-October 2024 period.
- Payor negotiations have led to discounted pricing for biosimilars in Europe and India.
- CMS reimbursement adjustments could accelerate price declines.
Key Risks
- Slow biosimilar adoption due to physician preference.
- Patent litigation extending exclusivity.
- Regulatory delays in biosimilar approval.
Summary
The primary product associated with NDC 70677-1061 is Eylea. Market value is declining as patent expiration approaches, with biosimilar entrants expected to reduce prices significantly from 2024 onward. The US market could see a 30-50% price reduction over the next six years, leading to lower revenues but broader access and potentially increased volume.
Key Takeaways
- Market size: Estimated at $4 billion in 2023, declining with biosimilar entry.
- Price trend: Branded injections at ~$2,000; projected to fall under $1,000 by 2028.
- Patent timeline: Eylea patent expires in October 2024, opening biosimilar competition.
- Competitive landscape: Biosimilars could capture significant US market share post-2024.
- Reimbursement policies: Will influence price and adoption rates.
FAQs
-
What is the primary indication for NDC 70677-1061?
Treats age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
-
When will biosimilars enter the US market?
Post-October 2024, following patent expiration and regulatory approval.
-
How much could prices decline for this drug?
Estimated 30-50% reduction over five years post-biosimilar entry.
-
What is the main driver for price decreases?
Patent expiration combined with biosimilar competition and payer negotiations.
-
What impact will biosimilars have on current market players?
Likely reduction in market share and revenues for the branded product, with increased competition and lower prices.
References
[1] Grand View Research. (2022). Anti-VEGF drugs market size, share & trends analysis.
[2] FDA. (2022). Biosimilar Approval and Regulatory Pathways.
[3] IQVIA. (2023). Healthcare Data & Market Analytics.
[4] U.S. Patent and Trademark Office. (2022). Patent expiry dates for Eylea.
